POSTER SESSION III Tuesday, March 25, 2003   —  9:30 AM - 12:00 Noon Exhibit Hall A - C GYNECOLOGIC PATHOLOGY 98 Prior Tubal Ligation Does Not Reduce the Frequency of Cortical Inclusion Cysts or Endometriosis of the Ovary (915) RC Mitrovich, AP Cviko, RA Betensky, MS Hirsch, CP Crum Brigham and Women's Hospital, Boston, MA; Harvard School of Public Health, Boston, MA 99 Protein Expression Study of Ovarian Surface Epithelial Neoplasms Using Tissue Microarray Analysis: Emergence of a Clear Cell Signature Profile (825) B Balzer, M Schaner, D Ross, K Montgomery, N Teng, B Sikic, T Longacre Stanford University, Stanford, CA; Applied Genomics, Inc, Sunnyvale, CA 100 Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer Is Histotype Specific (904) JS Liu, J Zhai, DG Rosen, K Lu, R Broaddus University of Texas MD Anderson Cancer Center, Houston, TX 101 Clear Cell Carcinoma of the Ovary and Endometrium Is Distinguished from Clear Cell Renal Cell Carcinoma Using CD10 Immunohistochemistry (942) JT Rabban, M Weinstein, CJ Zaloudek University of California, San Francisco, San Francisco, CA; San Francisco General Hospital, San Francisco, CA 102 The Use of Cytokeratin 7 in Differentiating Yolk Sac Tumors from Endometrioid and Clear Cell Carcinomas of the Ovary (943) P Ramalingam, A Malpica, EG Silva, JL Liu, DM Gershenson, MT Deavers University of Texas, M.D. Anderson Cancer Center, Houston, TX 103 Expression of Cellular Apoptosis Susceptibility Protein (CAS) and Apoptosis in Serous Ovarian Carcinoma (835) H Brustmann, S Naude Landeskrankenhaus, Moedling/Vienna, Austria 104 Immunohistochemical Expression of Gleevec-Sensitive Protein Tyrosine Kinases in Ovarian High Grade Serous Carcinoma (834) RR Broaddus, DM Gershenson, RE Schmandt UT M.D. Anderson Cancer Center, Houston, TX 105 Prognostic Tumor Markers in Ovarian Serous Carcinoma (SOC): A Study of One Hundred and Twenty Five Advanced Stage Cases (817) R Ali-Fehmi, AR Munkarah, M Che, S Bandyopadhyay, JM Malone, WD Lawrence Harper University Hospital; WSU, Detroit, MI; BMS, Providence, RI 106 Angiogenesis, Cyclooxygenase-2 and p53 Expression in Borderline, Low Grade and High Grade Ovarian Epithelial Neoplasms (930) V Pansare, R Ali-Fehmi, WD Lawerence, R Morris, AR Munkarah Harper University Hospital; The Karmanos Cancer Institute; Wayne State University, Detroit, MI; Brown Medical School, Providence, RI 107 Apolipoprotein E Expression in Ovarian Serous Carcinoma and Other Types of Cancer (845) C-C Cheng, Y-C Chen, A Maitra, RH Hruban, E Gabrison, RJ Kurman, I-M Shih Johns Hopkins Medical Institutions, Baltimore, MD 108 Comparative Analysis of Cell Cycle Regulatory Proteins and Cell Adhesion Molecules in Endometrioid Adenocarcinomas and Serous Papillary Carcinomas of the Ovary (848) ST Chuang, A Gupta, L Huo, P Keh, MS Rao Northwestern Memorial Hospital, Chicago, IL 109 Tumor Cell Proliferation Activity Correlates with Clinical Aggressiveness of Ovarian Serous Carcinomas (882) H Ji, G Singer, RJ Kurman, I-M Shih The Johns Hopkins Medical Institutions, Baltimore, MD 110 Cancer-Testis Antigen Expression in Papillary Serous Neoplasms of the Ovary (981) E Yakirevich, E Sabo, O Lavie, S Mazareb, GC Spagnoli, MB Resnick Carmel Medical Center, Haifa, Israel; University Hospital, Basel, Switzerland 111 Expression of Cancer Testis (CT) Antigens in Low Stage Epithelial Ovarian Tumors (883) AA Jungbluth, E Stockert, K Iversen, D Kolb, K Coplan, E Sato, M Leitao, RA Soslow Ludwig Institute for Cancer Research, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY 112 Overexpression of p53 Predicts Recurrence of Ovarian Cancer: A Tissue Microarray Study (897) SX Liang, HH Yu, BZ Senturk, V Parkash, D Rimm, W Zheng School of Medicine; Yale Univeristy, New Haven, CT 113 The Intestinal Marker Cdx2 Is Useful in Differentiating Primary Ovarian Carcinoma from Metastatic Colonic Carcinoma (866) GM Groisman, A Meir Hillel Yaffe Medical Center, Hadera, Israel 114 Expression of Androgen Receptor Coactivator 70 (ARA70) in Ovarian Cancer (905) JS Liu, P Lee, D Rosen, JA Thompson, KQ Cai, D McClain, A Malpica The University of Texas, M. D. Anderson Cancer Center, Houston, TX 115 Studies of APE/ref-1 Expression in Epithelial Ovarian Cancer: Correlations with Tumor Progression and Platinum Resistance (914) H Michael, S Freitas, DH Moore, MR Kelley Indiana University School of Medicine, Indianapolis, IN 116 The Utility of Inhibin, Calretinin and WT1 Immunohistochemical Staining in Ovarian Tumors (842) HP Cathro, MH Stoler University of Virginia, Charlottesville, VA 117 Prognostic Significance and Histotype-Specific Expression of Annexin I in Human Ovarian Cancers (813) C Albarracin, G Gibori, D Rosen, K Cai, J Liu M.D. Anderson Cancer Center, Houston, TX; University of Illinois at Chicago, Chicago, IL 118 Patterns of Loss of Heterozygosity (LOH) at 10q23.3 and Microsatellite Instability (MSI) in Ovarian Endometriosis(EN), Atypical Endometriosis(AEN) and Carcinoma (CA)Arising in Association with Endometriosis (828) S Bandyopadhyay, R Ali-Fehmi, AR Munkarah, E Silva, Q Du, D Liao The Karmanos Cancer Institute, Harper University Hospital, Wayne State University, Detroit, MI; M.D. Anderson, Houston, TX 119 Beta-Catenin Mutations, Microsatellite Instability, and hMLH1 Alterations in Ovarian Endometrioid Carcinomas (840) LI Catasus, IM Rodriguez, E Bussaglia, C Pons, J Munoz, S Ota, J Prat Hospital de la Santa Creu i Sant Pau. Autonomous University of Barcelona, Spain 120 X Chromosome Aneuploidy and Androgen Receptor Expression in Ovarian Carcinomas (843) C Cesca, K Atkins, P Papavassiliou, K Turner, C Jackson-Cook, J Ware Virginia Commonwealth University, Richmond, VA 121 Expression of p27 Tumor Suppressor Gene Is Not a Favorable Prognostic Marker for Human Ovarian Cancer (952) DG Rosen, J Liu The University of Texas M.D.Anderson Cancer Center, Houston, TX